IV ibuprofen is preferred over oral medications as it provides faster relief from pain and allows effective administration of medication to patients who have difficulty swallowing tablets or capsules.
The intravenous (IV) ibuprofen market comprises anti-inflammatory drugs that are administered intravenously for the treatment of pain associated with various conditions such as musculoskeletal injury, dental surgery, post-surgical pain management and headaches.
The Global Intravenous (IV) Ibuprofen Market is estimated to be valued at US$ 6.91 Bn in 2024 and is expected to exhibit a CAGR of 7.0% over the forecast period 2024 To 2031.
Key Takeaways
Key players operating in the intravenous (IV) ibuprofen market are Cumberland Pharmaceuticals Inc., Hyloris Pharmaceuticals SA, Grifols, S.A., Recordati Rare Diseases Inc., XGEN PHARMACEUTICALS DJB, Inc., AFT Pharmaceuticals, Laboratorios Valmorca, SGPharma Pvt. Ltd., Wellona Pharma, Delex Pharma, Hikma Pharmaceuticals PLC.
The increasing prevalence of musculoskeletal injuries, chronic pain disorders and postoperative pain is fueling the demand for IV ibuprofen formulation globally. Hospitalization rates have increased in recent years which has augmented the demand for analgesic drugs with fast onset of action and effective pain relief profile.
Major pharmaceutical companies are focusing on expansion in overseas markets to boost sales of IV ibuprofen formulations. Favorable reimbursement coverage for pain management drugs in countries like the U.S. further supports market growth. Pipeline candidates of existing brands are driving research activities to expand indication areas.
Market Key Trends
One of the key trends in the Intravenous (IV) Ibuprofen Market Size is the increase in clinical research for new indications. Pharma companies are conducting phase III/IV trials to evaluate IV ibuprofen efficacy in acute pain conditions like kidney stone pain, postoperative orthopedic pain and cesarean section pain management. This is expected to help gain insurance coverage and expand approved areas of use. Investments into innovative drug delivery systems like soft-gel capsules are also ongoing to enable self-administration and home healthcare of IV medications with less complexity.
Porter’s Analysis
Threat of new entrants: Low economies of scale and established distribution channels create entry barriers. Bargaining power of buyers: Commodity nature of product results in high buyer power. Bargaining power of suppliers: Few suppliers and differentiated products increase supplier power. Threat of new substitutes: New formulations regularly replace older generics, posing substitutes threat. Competitive rivalry: Significant capital requirements and patent expirations intensify competition.
Geographical Regions
North America accounts for the largest share of the intravenous (IV) ibuprofen market currently. The region's advanced healthcare infrastructure, availability of skilled professionals, and growing prevalence of pain disorders are major factors responsible for its large market size.
Asia Pacific is poised to be the fastest growing regional market over the forecast period from 2024 to 2031. This is attributed to rapidly developing economies, increasing healthcare investments, and rising geriatric population afflicted with orthopedic pain related issues in the region. Countries like China and India are main drivers of growth.
Get more insights on This Topic- Intravenous (IV) Ibuprofen Market
Comments
0 comment